Previous 10 | Next 10 |
Independent Data Monitoring Committee R ecommends C ontinuation of the Study with N o C hanges to Study Sample Size No Safety Concerns Identified Full Study Enrollment Expected by Year-End 2021; D ...
Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-ther...
MediWound (MDWD) jumps 17.6% premarket after announcing positive topline results from its Phase 3 pediatric clinical study (CIDS - Children Innovation Debridement Study) with NexoBrid to treat children with severe thermal burns, evaluating the efficacy and safety compared with stand...
NeuroBo Pharmaceuticals (NRBO) +36%.Immunome (IMNM) +29% rallies 31% after antibody cocktail neutralizes Delta variant in pre-clinical testingMediWound (MDWD) +19% announces positive topline results from Phase 3 pediatric ctudy (CIDS) of nexoBrid for eschar removal of seve...
YAVNE, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced positive topline results from its pivotal phase 3 pediatric ...
MediWound (MDWD) said that its wound debriding product candidate EscharEx met the main goal in a mid-stage trial in patients with a variety of chronic and hard-to-heal wounds.The company announces that a peer-reviewed publication, detailing the results of the phase 2 randomized cont...
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers Interim Assessment of Ongoing U.S. Phase II Adaptive Design Study in ...
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite (AMST) +22%.Global Internet of Peopl...
Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifescience...
MediWound (MDWD) announces that the U.S. FDA has declined to approve the company's NexoBrid treatment for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.The health regulator said that it had completed its review of the BLA, as amended, a...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...